Trials / Completed
CompletedNCT00987870
Safety and Efficacy of BFH772 in Psoriasis Patients
A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BFH772 | |
| DRUG | Placebo | |
| DRUG | BFH772 | |
| DRUG | Placebo | |
| DRUG | calcipotriol/betamethasone |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-02-01
- First posted
- 2009-10-01
- Last updated
- 2011-03-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00987870. Inclusion in this directory is not an endorsement.